Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
3.795
-0.005 (-0.13%)
Nov 21, 2024, 11:58 AM EST - Market open

Company Description

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.

Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix S.A.
Nanobiotix logo
Country France
Founded 2003
IPO Date Dec 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 102
CEO Laurent Levy

Contact Details

Address:
60 rue de Wattignies
Paris, 75012
France
Phone 33 1 40 26 04 70
Website nanobiotix.com

Stock Details

Ticker Symbol NBTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
IPO Price $13.50
CIK Code 0001760854
CUSIP Number 63009J107
ISIN Number US63009J1079
SIC Code 2834

Key Executives

Name Position
Laurent Levy Ph.D. Co-Founder, President of the Executive Board and Chief Executive Officer
Bart Van Rhijn Chief Financial and Business Officer and Member of Executive Board
Anne-Juliette Hermant M.A. Chief People Officer and Member of Executive Board
Dr. Louis Kayitalire M.D. Chief Medical Officer
Earl J. Bergey Ph.d. Co-Founder
Craig West CFA Senior Vice President of Investor Relations
Brandon Owens Vice President of Strategic Marketing and Corporate Communication
Margaret Galluzzi Vice President and Global Head of Clinical Operations
Dr. Leonard A. Farber M.D. Chief Clinical and Medical Affairs Officer and Chairman of the Scientific Advisory Board

Latest SEC Filings

Date Type Title
Nov 13, 2024 6-K Report of foreign issuer
Nov 12, 2024 6-K Report of foreign issuer
Oct 31, 2024 6-K Report of foreign issuer
Oct 11, 2024 6-K Report of foreign issuer
Sep 18, 2024 6-K Report of foreign issuer
Sep 18, 2024 6-K Report of foreign issuer
Sep 4, 2024 6-K Report of foreign issuer
Sep 3, 2024 6-K Report of foreign issuer
Aug 8, 2024 6-K Report of foreign issuer
Jul 9, 2024 6-K Report of foreign issuer